[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"NIPRO Technical Services, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":157},{"warningLetters":4,"total":156},[5,32,53,76,95,116,137],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},432,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-24T05:00:00Z\">11\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcdl-services-inc-dba-technichem-713877-11242025\">CDL Services, Inc. DBA Technichem \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-21\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luis F Salazar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CDL Services, Inc. DBA Technichem \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3800 E Miraloma Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Anaheim\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-21\u003C\u002Fp>\u003Cp>November 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Salazar:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection at CDL Services, Inc. DBA Technichem, FEI 3012112742, located at 3080 E La Jolla Street, Anaheim, CA, from April 7 to 28, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 15, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) drug products including hand sanitizers and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hand soap. Your firm failed to adequately test batches of your drug products for the identity and strength of your active ingredients (e.g., ethanol and chloroxylenol) before release and distribution. For example, you stated that finished product testing data provided during the inspection was generated using simulated results and that no testing had been performed on finished drug products in over a year. As a result, your firm released drug product to the market without appropriate testing, review, and approval to ensure satisfactory conformance to final specifications for strength and identity.\u003C\u002Fp>\u003Cp>In your response, you commit to testing products prior to distribution and testing the “most recently distributed” batches. Your response is inadequate in that it does not provide sufficient documentation for finished product testing (e.g., proposed test methodology or specifications). Moreover, your response fails to provide a timeline for when this testing will be completed or to perform any risk assessment.\u003C\u002Fp>\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fp>\u003Cul>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to ensure that components were suitable for use in manufacturing your OTC drug products. For example, you did not perform identity testing on each shipment of each lot of incoming components, such as glycerin, ethanol and chloroxylenol. Additionally, you relied on your suppliers’ certificates of analysis without verifying your supplier’s test results at appropriate intervals. Furthermore, you have not ensured that water used as a component is suitable for its intended use (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, United States Pharmacopeia (USP) monograph).\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming component ethyl alcohol (ethanol) at risk of methanol contamination for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin and propylene glycol to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\u003C\u002Fp>\u003Cp>Identity testing for glycerin, propylene glycol and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Water Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Moreover, your firm uses water as a component in the manufacture of your drug products. Your firm has not demonstrated that the water is suitable for its intended use in pharmaceutical manufacturing. At a minimum, such water must meet the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph and appropriate microbial limits.\u003C\u002Fp>\u003Cp>In your response, you commit to performing identity testing of components, testing for methanol and DEG\u002FEG in high-risk components, and testing of your water used as a component. Your response is inadequate in that you did not provide a detailed plan for how your components will be assessed against compendial requirements. Furthermore, it did not include sufficient information regarding test methods or a timeline for implementing the proposed corrective actions.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test each incoming lot of components, including high-risk drug components, to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures your water system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) lacked adequate control over your OTC drug product manufacturing operations and failed to ensure that you had adequate procedures. For example, your quality unit (QU) failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate procedures describing the roles and responsibilities of the QU, including review of complaints, supplier qualification, change control and periodic product quality review (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fli>\u003Cli>Establishment of appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).\u003C\u002Fli>\u003Cli>Establishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Drug products bear expiration dates that are supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to establishing a dedicated QU with associated procedures. Your response is inadequate in that it lacks detail on systemic remediations for your QU and improvements to your quality system. Your response also fails to provide details on how your QU will have the responsibility and authority to perform its functions.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Access to Information During Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the gas chromatograph and the associated CGMP computer system were not available to the inspection team. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\u003C\u002Fp>\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document \u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\u003C\u002Fem> for guidance on implementing modern quality systems and risk management approaches to meet the requirements of the Agency's CGMP regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug man-ufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012112742 and ATTN: Andrew Haack, Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-21\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luis F Salazar\n\nRecipient Title\n\nPresident\u002FCEO\n\nCDL Services, Inc. DBA Technichem\n\n3800 E Miraloma Avenue\n\nAnaheim, CA 92806\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-21\nNovember 24, 2025\nDear Mr. Salazar:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection at CDL Services, Inc. DBA Technichem, FEI 3012112742, located at 3080 E La Jolla Street, Anaheim, CA, from April 7 to 28, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 15, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures over-the-counter (OTC) drug products including hand sanitizers and (b)(4) hand soap. Your firm failed to adequately test batches of your drug products for the identity and strength of your active ingredients (e.g., ethanol and chloroxylenol) before release and distribution. For example, you stated that finished product testing data provided during the inspection was generated using simulated results and that no testing had been performed on finished drug products in over a year. As a result, your firm released drug product to the market without appropriate testing, review, and approval to ensure satisfactory conformance to final specifications for strength and identity.\nIn your response, you commit to testing products prior to distribution and testing the “most recently distributed” batches. Your response is inadequate in that it does not provide sufficient documentation for finished product testing (e.g., proposed test methodology or specifications). Moreover, your response fails to provide a timeline for when this testing will be completed or to perform any risk assessment.\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\nIn response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to ensure that components were suitable for use in manufacturing your OTC drug products. For example, you did not perform identity testing on each shipment of each lot of incoming components, such as glycerin, ethanol and chloroxylenol. Additionally, you relied on your suppliers’ certificates of analysis without verifying your supplier’s test results at appropriate intervals. Furthermore, you have not ensured that water used as a component is suitable for its intended use (e.g., (b)(4) Water, United States Pharmacopeia (USP) monograph).\nProducts Containing Ethanol\nYou failed to adequately test your incoming component ethyl alcohol (ethanol) at risk of methanol contamination for identity before using it as an active pharmaceutical ingredient (API) in manufacturing your OTC topical drug products. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nProducts Containing Ingredients at Risk for Diethylene Glycol or Ethylene Glycol (DEG or EG) Contamination\nYou also failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin and propylene glycol to determine its appropriate identity, prior to use in manufacturing your OTC topical drug products.\nIdentity testing for glycerin, propylene glycol and certain other high-risk drug components includes a limit test in the USP to ensure the component meets the relevant safety limits for DEG or EG levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nWater Used as a Component in Drug Products\nMoreover, your firm uses water as a component in the manufacture of your drug products. Your firm has not demonstrated that the water is suitable for its intended use in pharmaceutical manufacturing. At a minimum, such water must meet the (b)(4) Water, USP monograph and appropriate microbial limits.\nIn your response, you commit to performing identity testing of components, testing for methanol and DEG\u002FEG in high-risk components, and testing of your water used as a component. Your response is inadequate in that you did not provide a detailed plan for how your components will be assessed against compendial requirements. Furthermore, it did not include sufficient information regarding test methods or a timeline for implementing the proposed corrective actions.\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA summary of results obtained from testing all components to evaluate the reliability of the certificate of analysis (COA) from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical and microbiological quality control specifications you use to test each incoming lot of components, including high-risk drug components, to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA commitment to provide methanol test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of methanol.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures your water system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) lacked adequate control over your OTC drug product manufacturing operations and failed to ensure that you had adequate procedures. For example, your quality unit (QU) failed to ensure the following:\nEstablishment of adequate procedures describing the roles and responsibilities of the QU, including review of complaints, supplier qualification, change control and periodic product quality review (21 CFR 211.22(a) and 211.22(d)).\nEstablishment of appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records or other records (21 CFR 211.68(b)).\nEstablishment of adequate production procedures and process control to assure your drug products have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nDrug products bear expiration dates that are supported by appropriate stability testing (21 CFR 211.137(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\nIn your response, you commit to establishing a dedicated QU with associated procedures. Your response is inadequate in that it lacks detail on systemic remediations for your QU and improvements to your quality system. Your response also fails to provide details on how your QU will have the responsibility and authority to perform its functions.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\nAccess to Information During Inspection\nDuring the inspection, the gas chromatograph and the associated CGMP computer system were not available to the inspection team. This limited FDA’s access to records for inspection to evaluate the CGMP compliance status of your facility.\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA. See FDA’s guidance document Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations for guidance on implementing modern quality systems and risk management approaches to meet the requirements of the Agency's CGMP regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug man-ufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012112742 and ATTN: Andrew Haack, Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","CDL Services, Inc. DBA Technichem","cdl-services-inc-dba-technichem-713877-11242025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcdl-services-inc-dba-technichem-713877-11242025","2026-10-26T08:08:12.259717+00:00","Warning Letter","Issued","2025-12-09","713877","Drugs Over-the-Counter Drugs","Mr. Luis F Salazar","2026-08-19T11:13:37.324+00:00","VIA UPS","320-26-21","2025-11-24",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},3703,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026\">D&amp;H Medical Services\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>D&amp;H Medical Services\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 NW 79th Avenue, Suite 265\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@dhmedicalcenter.com\"> info@dhmedicalcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728238\u003C\u002Fp>\u003Cp>To D&amp;H Medical Services:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of D&amp;H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same ingredient as Rybelsus®”\u003C\u002Fli>\u003Cli>“Same ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nD&H Medical Services\n\n2500 NW 79th Avenue, Suite 265\n\nDoral, FL 33122\n\nUnited States\n\ninfo@dhmedicalcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728238\nTo D&H Medical Services:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of D&H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same ingredient as Ozempic®”\n“Same ingredient as Rybelsus®”\n“Same ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","D&H Medical Services","dh-medical-services-728238-06082026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026","2026-10-26T08:08:24.115003+00:00","2026-06-16","728238","Drugs","2026-08-19T04:34:50.914+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":59,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},543,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025\">New Life Medical Services, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-711102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joshua M. Mansavage\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Life Medical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>244 Crystal Grove Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lutz\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33548-6460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Joshm@newliferegen.com\"> Joshm@newliferegen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 24, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25- 711102\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Mansavage:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\u003C\u002Fli>\u003Cli>Your Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\u003C\u002Fli>\u003Cli>Your training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\u003C\u002Fli>\u003Cli>Your package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\u003C\u002Fli>\u003Cli>Your Physician Guide states:\u003Cbr>o “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\u003Cbr>o Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\u003C\u002Fli>\u003Cli>Your product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\u003C\u002Fli>\u003Cli>Your website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\u003C\u002Fli>\u003Cli>One of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have concerns about the following products:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&amp;C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\u003C\u002Fli>\u003Cli>We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-711102\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoshua M. Mansavage\n\nRecipient Title\n\nChief Executive Officer\n\nNew Life Medical Services, LLC\n\n244 Crystal Grove Blvd\n\nLutz, FL 33548-6460\n\nUnited States\n\nJoshm@newliferegen.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 24, 2025\nCBER 25- 711102\nDear Mr. Mansavage:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+1, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes2), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\nYour Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\nYour training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\nYour package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\nYour Physician Guide states:\no “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\no Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\nYour product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\nYour website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\nOne of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\nIn addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nAdditional Concerns\nIn addition to the violations described above, we have concerns about the following products:\nFDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge4. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\nWe also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\n2 You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\n3 Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\n4 Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”","New Life Medical Services, LLC","new-life-medical-services-llc-711102-09242025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025","2026-10-26T08:09:32.410522+00:00","2025-10-07","711102","Biologics","Joshua M. Mansavage","2026-08-19T16:15:04.082+00:00","VIA UPS and Electronic Mail","CBER 25-711102","2025-09-24",{"id":77,"raw":78,"subject":12,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":65,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":93,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},527,[79,80,81,11,12,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-17T04:00:00Z\">09\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrs-analytical-services-llc-711133-09172025\">BRS Analytical Services, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-112\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Teresa L. Bandrowsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BRS Analytical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11697 Lakeside Crossing Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>St. Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63146-8606\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-112\u003C\u002Fp>\u003Cp>September 17, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Bandrowsky:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility and contract testing laboratory, BRS Analytical Services, LLC, FEI 3023604380, at 11697 Lakeside Crossing Court, St. Louis, from March 10 to 26, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 14, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Cleanroom Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your ISO 5 area used for aseptic compounding and filling sterile over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was fundamentally unsuitable for its intended use. For example, your ISO 5 area had gaps in the wall intended to separate it from the immediately surrounding unclassified warehouse, including large gaps between most wall sections and the floor. Some of these gaps contained mesh screens that appeared to be dirty. Furthermore, you failed to maintain an adequate differential pressure between the ISO 5 area and the warehouse, and did not continuously monitor that pressure. The lack of both physical and aerodynamic segregation in your aseptic processing facility design posed an unacceptable risk to product sterility.\u003C\u002Fp>\u003Cp>The ISO 5 area is critical because sterile drug products are exposed and are therefore vulnerable to contamination. Your aseptic manufacturing facility, equipment, and process must be designed, and operations must be executed, to minimize contamination hazards to your sterile drug product. The unacceptable design of your operation precluded the ability to maintain asepsis.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to establish an adequate system for monitoring environmental conditions. For example, you did not routinely perform viable air monitoring during production, despite a procedural requirement to do so. In addition, your nonviable particle monitor was placed on top of the enclosed cabinet in which filling occurred instead of inside it, rendering the resulting data non-representative of the environmental conditions near the areas of critical exposure on the aseptic processing line. Finally, you failed to routinely review environmental monitoring data prior to batch release.\u003C\u002Fp>\u003Cp>Vigilant and responsive environmental and personnel monitoring programs provide meaningful information on the state of control of the aseptic processing operation, and enable an early warning system that identifies emerging contamination hazards before sterility is compromised. Operations that include highly \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to an emphasis on increased sampling that monitors ongoing batch production conditions more extensively.\u003C\u002Fp>\u003Cp>\u003Cem>Facility Maintenance Deficiencies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection, we observed your facility to be in a state of disrepair or unclean in several instances. This includes, but is not limited to, the following deficiencies within your aseptic processing room:\u003C\u002Fp>\u003Cp>• Discoloration and apparent residue on light panels above the aseptic filling equipment during operations.\u003Cbr>• Chipped paint on a floor scale.\u003Cbr>• Discoloration on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizer and a table.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed poor practices in ISO 5 areas during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive aseptic processing of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, including but not limited to:\u003C\u002Fp>\u003Cp>• Operators blocked unidirectional airflow during routine production by placing their gloved hands and hooded, masked heads directly over open sterilized bottles.\u003Cbr>• The skin surrounding operators’ safety glasses was exposed in the ISO 5 area.\u003Cbr>• Use of nonsterile face masks.\u003Cbr>• Use of nonsterile paper towels in the ISO 5 area, including inside the filling cabinet.\u003Cbr>• Failure to seal a vessel containing sterile drug product. Instead of a securely fitted cap, you used an \u003Cstrong>(b)(4)\u003C\u002Fstrong> intended to cover an open port in the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> holding tank in the ISO 5 area during the filling process, which was typically run for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days and did not include additional sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, our investigators observed condensation inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as air gaps that provided an avenue for ingress of \u003Cstrong>(b)(4)\u003C\u002Fstrong> air.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate commercial operations. You only incubated approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of units for each media fill, rather than \u003Cstrong>(b)(4)\u003C\u002Fstrong> units. In contrast, your protocols required \u003Cstrong>(b)(4)\u003C\u002Fstrong> units that passed inspection to be incubated. In addition, each media fill lasted only approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> or less, although your commercial aseptic filling operations typically lasted \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\u003Cp>It is essential that \u003Cstrong>(b)(4)\u003C\u002Fstrong> media fill units be incubated and examined for evidence of microbial contamination. Also, to accurately simulate contamination risks, the duration of the process simulation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive lines normally should be no less than the length of the actual manufacturing process.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Assurance of Sterilization\u003C\u002Fem>\u003C\u002Fp>\u003Cp>• The validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process used to sterilize direct product contact parts, including transfer hoses and sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was inadequate. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation process did not include the use of biological indicators. Instead, \u003Cstrong>(b)(4)\u003C\u002Fstrong> water was placed in jars and tested for sterility. Notably, one of these jars of water tested positive for growth, but you did not conduct an investigation.\u003Cbr>• Sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not integrity tested for each batch of drug products manufactured.\u003C\u002Fp>\u003Cp>It is essential that product contact equipment is sterile to be suitable for its intended use. Sterilization cycle validation is established through studies that incorporate rigorous physical and biological measurements. Between uses, sterile equipment must be held under ISO 5 conditions and continuously maintained in a manner that prevents contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Study\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your smoke study did not adequately demonstrate unidirectional air flow in the ISO 5 area that was used for the aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example:\u003C\u002Fp>\u003Cp>• Your smoke study did not evaluate unidirectionality. Instead, you turned off the HEPA-\u003Cstrong>(b)(4)\u003C\u002Fstrong> fans, filled the ISO 5 area with smoke, then turned the fans on and verified that the room was cleared of smoke.\u003Cbr>• You failed to conduct a smoke study with your actual filling equipment present.\u003Cbr>• Your smoke study was not conducted under dynamic conditions.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to maintain adequate CGMP oversight and allowed the distribution of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products manufactured under unacceptable conditions, which included poorly designed facilities, an unsuitable aseptic manufacturing process, and deficient environmental monitoring. You also failed to ensure implementation of an effective qualification and validation program, and perform adequate antimicrobial effectiveness studies for your multi-dose aqueous-based sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>In addition, you failed to ensure that adequate procedures were followed describing the roles and responsibilities of the QU including, but not limited to, raw material supplier qualification.\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU was not fully exercising its authority or responsibility. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On April 17, 2025, FDA held a teleconference with you recommending that you remove from the U.S. market all batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products currently in distribution. On April 21, 2025, you committed to ceasing the manufacture and distribution of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products and agreed to a voluntary recall of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products currently in distribution in the U.S. On April 23, 2025, you issued a voluntary recall of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products due to CGMP deviations and lack of assurance of sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=96741.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment dated June 24, 2025, to permanently cease production of all drugs at this facility.\u003C\u002Fp>\u003Cp>Notify this office if you intend to resume your drug manufacturing operations at this site or in another location. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3023604380 and ATTN: Russell Riley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>_____________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-112\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Teresa L. Bandrowsky\n\nRecipient Title\n\nOwner\n\nBRS Analytical Services, LLC\n\n11697 Lakeside Crossing Court\n\nSt. Louis, MO 63146-8606\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-112\nSeptember 17, 2025\nDear Ms. Bandrowsky:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility and contract testing laboratory, BRS Analytical Services, LLC, FEI 3023604380, at 11697 Lakeside Crossing Court, St. Louis, from March 10 to 26, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 14, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 211.63).\nCleanroom Design\nYour ISO 5 area used for aseptic compounding and filling sterile over-the-counter (OTC) (b)(4) drug products was fundamentally unsuitable for its intended use. For example, your ISO 5 area had gaps in the wall intended to separate it from the immediately surrounding unclassified warehouse, including large gaps between most wall sections and the floor. Some of these gaps contained mesh screens that appeared to be dirty. Furthermore, you failed to maintain an adequate differential pressure between the ISO 5 area and the warehouse, and did not continuously monitor that pressure. The lack of both physical and aerodynamic segregation in your aseptic processing facility design posed an unacceptable risk to product sterility.\nThe ISO 5 area is critical because sterile drug products are exposed and are therefore vulnerable to contamination. Your aseptic manufacturing facility, equipment, and process must be designed, and operations must be executed, to minimize contamination hazards to your sterile drug product. The unacceptable design of your operation precluded the ability to maintain asepsis.\nEnvironmental Monitoring\nYou failed to establish an adequate system for monitoring environmental conditions. For example, you did not routinely perform viable air monitoring during production, despite a procedural requirement to do so. In addition, your nonviable particle monitor was placed on top of the enclosed cabinet in which filling occurred instead of inside it, rendering the resulting data non-representative of the environmental conditions near the areas of critical exposure on the aseptic processing line. Finally, you failed to routinely review environmental monitoring data prior to batch release.\nVigilant and responsive environmental and personnel monitoring programs provide meaningful information on the state of control of the aseptic processing operation, and enable an early warning system that identifies emerging contamination hazards before sterility is compromised. Operations that include highly (b)(4) intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to an emphasis on increased sampling that monitors ongoing batch production conditions more extensively.\nFacility Maintenance Deficiencies\nDuring the inspection, we observed your facility to be in a state of disrepair or unclean in several instances. This includes, but is not limited to, the following deficiencies within your aseptic processing room:\n• Discoloration and apparent residue on light panels above the aseptic filling equipment during operations.\n• Chipped paint on a floor scale.\n• Discoloration on the (b)(4) sterilizer and a table.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Behavior\nWe observed poor practices in ISO 5 areas during your (b)(4) intensive aseptic processing of sterile (b)(4) drug products, including but not limited to:\n• Operators blocked unidirectional airflow during routine production by placing their gloved hands and hooded, masked heads directly over open sterilized bottles.\n• The skin surrounding operators’ safety glasses was exposed in the ISO 5 area.\n• Use of nonsterile face masks.\n• Use of nonsterile paper towels in the ISO 5 area, including inside the filling cabinet.\n• Failure to seal a vessel containing sterile drug product. Instead of a securely fitted cap, you used an (b)(4) intended to cover an open port in the sterile (b)(4) holding tank in the ISO 5 area during the filling process, which was typically run for (b)(4) days and did not include additional sterilizing (b)(4). In addition, our investigators observed condensation inside the (b)(4), as well as air gaps that provided an avenue for ingress of (b)(4) air.\nInadequate Media Fill Program\nYour media fills failed to accurately simulate commercial operations. You only incubated approximately (b)(4) of units for each media fill, rather than (b)(4) units. In contrast, your protocols required (b)(4) units that passed inspection to be incubated. In addition, each media fill lasted only approximately (b)(4) or less, although your commercial aseptic filling operations typically lasted (b)(4) days.\nIt is essential that (b)(4) media fill units be incubated and examined for evidence of microbial contamination. Also, to accurately simulate contamination risks, the duration of the process simulation for (b)(4) intensive lines normally should be no less than the length of the actual manufacturing process.\nInadequate Assurance of Sterilization\n• The validation of the (b)(4) sterilization process used to sterilize direct product contact parts, including transfer hoses and sterilizing (b)(4), was inadequate. For example, the (b)(4) sterilization validation process did not include the use of biological indicators. Instead, (b)(4) water was placed in jars and tested for sterility. Notably, one of these jars of water tested positive for growth, but you did not conduct an investigation.\n• Sterilizing (b)(4) were not integrity tested for each batch of drug products manufactured.\nIt is essential that product contact equipment is sterile to be suitable for its intended use. Sterilization cycle validation is established through studies that incorporate rigorous physical and biological measurements. Between uses, sterile equipment must be held under ISO 5 conditions and continuously maintained in a manner that prevents contamination.\nInadequate Smoke Study\nYour smoke study did not adequately demonstrate unidirectional air flow in the ISO 5 area that was used for the aseptic filling of (b)(4) drug products. For example:\n• Your smoke study did not evaluate unidirectionality. Instead, you turned off the HEPA-(b)(4) fans, filled the ISO 5 area with smoke, then turned the fans on and verified that the room was cleared of smoke.\n• You failed to conduct a smoke study with your actual filling equipment present.\n• Your smoke study was not conducted under dynamic conditions.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\nYour quality unit (QU) failed to maintain adequate CGMP oversight and allowed the distribution of sterile (b)(4) drug products manufactured under unacceptable conditions, which included poorly designed facilities, an unsuitable aseptic manufacturing process, and deficient environmental monitoring. You also failed to ensure implementation of an effective qualification and validation program, and perform adequate antimicrobial effectiveness studies for your multi-dose aqueous-based sterile (b)(4) drug products.\nIn addition, you failed to ensure that adequate procedures were followed describing the roles and responsibilities of the QU including, but not limited to, raw material supplier qualification.\nSignificant findings in this letter indicate that your QU was not fully exercising its authority or responsibility. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nDrug Recall\nOn April 17, 2025, FDA held a teleconference with you recommending that you remove from the U.S. market all batches of (b)(4) drug products currently in distribution. On April 21, 2025, you committed to ceasing the manufacture and distribution of all (b)(4) drug products and agreed to a voluntary recall of all (b)(4) drug products currently in distribution in the U.S. On April 23, 2025, you issued a voluntary recall of all (b)(4) drug products due to CGMP deviations and lack of assurance of sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=96741.\nDrug Production Ceased\nWe acknowledge your commitment dated June 24, 2025, to permanently cease production of all drugs at this facility.\nNotify this office if you intend to resume your drug manufacturing operations at this site or in another location. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPA).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive (b)(4)1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3023604380 and ATTN: Russell Riley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: (b)(4)\n(b)(6), (b)(7)(C)\n_____________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","BRS Analytical Services, LLC","brs-analytical-services-llc-711133-09172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrs-analytical-services-llc-711133-09172025","2026-10-26T08:08:09.185449+00:00","2025-10-21","711133","Ms. Teresa L. Bandrowsky","2026-08-19T16:13:17.32+00:00","VIA EMAIL WITH READ RECEIPT","320-25-112","2025-09-17",{"id":96,"raw":97,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":23,"posted_date":110,"marcs_cms_no":111,"product_type":112,"closeout_date":19,"issuing_office":101,"recipient_name":113,"body_fetched_at":114,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},2089,[98,99,100,101,102,13,13,13],"\u003Ctime datetime=\"2023-05-30T13:20:00Z\">05\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-17T04:00:00Z\">05\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsm-services-llc-658870-05172023\">GSM Services, LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Carlos Hernandez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>GSM Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7533 4th Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Downey\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90241\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:GSMSERVICES552@GMAIL.COM\"> GSMSERVICES552@GMAIL.COM\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 17, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hernandez,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that GSM Services, LLC. is a domestic importer of pipe tobacco, cigars, and roll-your-own tobacco products for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&amp;C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer of certain tobacco products, including pipe tobacco, cigars, and roll-your-own tobacco, remit payment of its user fee assessment by the last day of the applicable quarter.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Pay Assessed User Fees\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that all regulated tobacco products imported by GSM Services, LLC. are adulterated under section 902(4) of the FD&amp;C Act (21 U.S.C. § 387b(4)) because you have failed to pay user fees assessed to you as required by section 919 of the FD&amp;C Act (21 U.S.C. § 387s). Specifically, based on our records, you import tobacco products into the United States, you import products subject to user fees under section 919 of the FD&amp;C Act, and you were assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. Section 919(b)(6) of the FD&amp;C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. To date, FDA has not received payment from you for the invoices enumerated in the table below.\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Fiscal Quarter\u002FYear of Liability\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Assessment Invoice Date\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Assessment Due Date\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>2\u003Csup>nd\u003C\u002Fsup> Quarter 2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F1\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F31\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u003Csup>rd\u003C\u002Fsup> Quarter 2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>6\u002F1\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>7\u002F1\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>1\u003Csup>st\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F1\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F31\u002F2019\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>2\u003Csup>nd\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F1\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u003Csup>rd\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>5\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>6\u002F30\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>1\u003Csup>st\u003C\u002Fsup> Quarter 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F1\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F31\u002F2020\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>2\u003Csup>nd\u003C\u002Fsup> Quarter 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F1\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F31\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u003Csup>rd\u003C\u002Fsup> Quarter 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>5\u002F31\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>6\u002F30\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u003Csup>rd\u003C\u002Fsup> Quarter 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>5\u002F31\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>6\u002F30\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>1\u003Csup>st\u003C\u002Fsup> Quarter 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F1\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F31\u002F2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>2\u003Csup>nd\u003C\u002Fsup> Quarter 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F1\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u002F31\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>3\u003Csup>rd\u003C\u002Fsup> Quarter 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>5\u002F31\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>6\u002F30\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>4\u003Csup>th\u003C\u002Fsup> Quarter 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>8\u002F31\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F30\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>1\u003Csup>st, \u003C\u002Fsup>2\u003Csup>nd\u003C\u002Fsup> 3\u003Csup>rd\u003C\u002Fsup>, and 4\u003Csup>th\u003C\u002Fsup> Quarter 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F1\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>12\u002F31\u002F2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>Because you have failed to pay user fees assessed pursuant to section 919 of the FD&amp;C Act by the date specified in section 919, regulated tobacco products imported by GSM Services, LLC. are adulterated under section 902(4) of the FD&amp;C Act (21 U.S.C. § 387b(4)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\u003C\u002Fp>\n\n\u003Cp>In addition, compliance with the requirements of the FD&amp;C Act under section 910(a)(2)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&amp;C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until a firm has paid its assessed fees in their entirety.\u003C\u002Fp>\n\n\u003Cp>Please note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&amp;C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&amp;C Act) and thus its products are adulterated.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance and your plan for maintaining compliance with the FD&amp;C Act. Your response should include:\u003C\u002Fp>\n\n\u003Cp>1. Documentation showing that you have paid or have contacted OFM at userfees@fda.gov for information on how to pay your assessed user fees and set up a plan to pay those fees.\u003C\u002Fp>\n\n\u003Cp>2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\u003C\u002Fp>\n\n\u003Cp>3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300850, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>or\u003C\u002Fp>\n\n\u003Cp>ctpcompliance@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at (301) 796-4083 or kristina.peters@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nCarlos Hernandez\n\nGSM Services, LLC\n\n7533 4th Place\n\nDowney, CA 90241\n\nUnited States\n\nGSMSERVICES552@GMAIL.COM\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nMay 17, 2023\n\nDear Mr. Hernandez,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that GSM Services, LLC. is a domestic importer of pipe tobacco, cigars, and roll-your-own tobacco products for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer of certain tobacco products, including pipe tobacco, cigars, and roll-your-own tobacco, remit payment of its user fee assessment by the last day of the applicable quarter.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nFailure to Pay Assessed User Fees\n\nFDA has determined that all regulated tobacco products imported by GSM Services, LLC. are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)) because you have failed to pay user fees assessed to you as required by section 919 of the FD&C Act (21 U.S.C. § 387s). Specifically, based on our records, you import tobacco products into the United States, you import products subject to user fees under section 919 of the FD&C Act, and you were assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. To date, FDA has not received payment from you for the invoices enumerated in the table below.\n\nFiscal Quarter\u002FYear of Liability\n\nAssessment Invoice Date\n\nAssessment Due Date\n\n2nd Quarter 2019\n\n3\u002F1\u002F2019\n\n3\u002F31\u002F2019\n\n3rd Quarter 2019\n\n6\u002F1\u002F2019\n\n7\u002F1\u002F2019\n\n4th Quarter 2019\n\n8\u002F31\u002F2019\n\n9\u002F30\u002F2019\n\n4th Quarter 2019\n\n8\u002F31\u002F2019\n\n9\u002F30\u002F2019\n\n1st Quarter 2020\n\n12\u002F1\u002F2019\n\n12\u002F31\u002F2019\n\n2nd Quarter 2020\n\n3\u002F1\u002F2020\n\n3\u002F31\u002F2020\n\n3rd Quarter 2020\n\n5\u002F31\u002F2020\n\n6\u002F30\u002F2020\n\n4th Quarter 2020\n\n8\u002F31\u002F2020\n\n9\u002F30\u002F2020\n\n4th Quarter 2020\n\n8\u002F31\u002F2020\n\n9\u002F30\u002F2020\n\n4th Quarter 2020\n\n8\u002F31\u002F2020\n\n9\u002F30\u002F2020\n\n1st Quarter 2021\n\n12\u002F1\u002F2020\n\n12\u002F31\u002F2020\n\n2nd Quarter 2021\n\n3\u002F1\u002F2021\n\n3\u002F31\u002F2021\n\n3rd Quarter 2021\n\n5\u002F31\u002F2021\n\n6\u002F30\u002F2021\n\n3rd Quarter 2021\n\n5\u002F31\u002F2021\n\n6\u002F30\u002F2021\n\n4th Quarter 2021\n\n8\u002F31\u002F2021\n\n9\u002F30\u002F2021\n\n1st Quarter 2022\n\n12\u002F1\u002F2021\n\n12\u002F31\u002F2021\n\n2nd Quarter 2022\n\n3\u002F1\u002F2022\n\n3\u002F31\u002F2022\n\n3rd Quarter 2022\n\n5\u002F31\u002F2022\n\n6\u002F30\u002F2022\n\n4th Quarter 2022\n\n8\u002F31\u002F2022\n\n9\u002F30\u002F2022\n\n1st, 2nd 3rd, and 4th Quarter 2022\n\n12\u002F1\u002F2022\n\n12\u002F31\u002F2022\n\nBecause you have failed to pay user fees assessed pursuant to section 919 of the FD&C Act by the date specified in section 919, regulated tobacco products imported by GSM Services, LLC. are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)).\n\nConclusion and Requested Actions\n\nUnder section 301(a) of the FD&C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\n\nIn addition, compliance with the requirements of the FD&C Act under section 910(a)(2)(A)(i) of the FD&C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until a firm has paid its assessed fees in their entirety.\n\nPlease note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&C Act) and thus its products are adulterated.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance and your plan for maintaining compliance with the FD&C Act. Your response should include:\n\n1. Documentation showing that you have paid or have contacted OFM at userfees@fda.gov for information on how to pay your assessed user fees and set up a plan to pay those fees.\n\n2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\n\n3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300850, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nor\n\nctpcompliance@fda.hhs.gov\n\nIf you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at (301) 796-4083 or kristina.peters@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","GSM Services, LLC","gsm-services-llc-658870-05172023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgsm-services-llc-658870-05172023","2026-10-26T08:08:50.993994+00:00","2023-05-30","658870","Tobacco","Carlos Hernandez","2026-08-20T01:05:31.659+00:00","2023-05-17",{"id":117,"raw":118,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":107,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":132,"closeout_date":19,"issuing_office":122,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},2313,[119,120,121,122,123,13,13,13],"\u003Ctime datetime=\"2022-11-29T14:20:00Z\">11\u002F29\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-01T04:00:00Z\">06\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjam-jam-services-inc-630847-06012022\">Jam Jam Services, Inc.\u003C\u002Fa>","Division of Southeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David G. Johnson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jam Jam Services, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5401 NW 102nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sunrise\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33351-8745\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS 630847\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnson:\u003C\u002Fp>\n\n\u003Cp>On January 25, 2022, through February 3, 2022, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Jam Jam Services, Inc., located at 5401 NW 102nd Ave. Sunrise, FL 33351. We also conducted an inspection on December 30, 2020, through February 1, 2021, and on May 14, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the initial FSVP inspection in 2019, the follow-up inspection in 2020, and the compliance follow-up inspection in 2022, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to any of the Form FDA-483a’s.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products that you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Powdered Scotch Bonnet Peppers, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>Beverage Mix Coconut Flavor, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. § 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Ms. Ruth Dixon, Program Division Director, Division of Southeast Imports, 404 BNA Drive, Building 200 - Suite 500 Nashville, TN 37217-2565. If you have any questions regarding this letter, you may contact Ms. Coral del Mar Lopez, Compliance Officer via email at coraldelmar.lopez@fda.hhs.gov. Please reference CMS #630847 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ruth Dixon\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. David G. Johnson\n\nRecipient Title\n\nPresident\n\nJam Jam Services, Inc.\n\n5401 NW 102nd Ave\n\nSunrise, FL 33351-8745\n\nUnited States\n\nIssuing Office:\n\nDivision of Southeast Imports\n\nUnited States\n\nJune 1, 2022\n\nWARNING LETTER\n\nRe: CMS 630847\n\nDear Mr. Johnson:\n\nOn January 25, 2022, through February 3, 2022, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Jam Jam Services, Inc., located at 5401 NW 102nd Ave. Sunrise, FL 33351. We also conducted an inspection on December 30, 2020, through February 1, 2021, and on May 14, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the initial FSVP inspection in 2019, the follow-up inspection in 2020, and the compliance follow-up inspection in 2022, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to any of the Form FDA-483a’s.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products that you import, including:\n\nPowdered Scotch Bonnet Peppers, imported from (b)(4), located in (b)(4).\n\nBeverage Mix Coconut Flavor, imported from (b)(4), located in (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. § 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Ms. Ruth Dixon, Program Division Director, Division of Southeast Imports, 404 BNA Drive, Building 200 - Suite 500 Nashville, TN 37217-2565. If you have any questions regarding this letter, you may contact Ms. Coral del Mar Lopez, Compliance Officer via email at coraldelmar.lopez@fda.hhs.gov. Please reference CMS #630847 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nRuth Dixon\n\nProgram Division Director\n\nDivision of Southeast Imports","Jam Jam Services, Inc.","jam-jam-services-inc-630847-06012022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjam-jam-services-inc-630847-06012022","2026-10-26T08:09:02.631756+00:00","2022-11-29","630847","Food & Beverages","Mr. David G. Johnson","2026-08-20T01:23:52.38+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-06-01",{"id":138,"raw":139,"subject":123,"body_html":144,"body_text":145,"firm_name":146,"letter_id":147,"created_at":148,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":132,"closeout_date":19,"issuing_office":143,"recipient_name":153,"body_fetched_at":154,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":155,"medical_device_id":19,"response_letter_date":19},3137,[140,141,142,143,123,13,13,13],"\u003Ctime datetime=\"2021-09-21T13:20:00Z\">09\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-29T04:00:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffmt-services-llc-614466-06292021\">FMT Services, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Fabian Gonzalez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>FMT Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4516 Queenswood Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grand Prairie\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75052-8332\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 29, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS# 614466\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gonzalez:\u003C\u002Fp>\n\n\u003Cp>On March 22, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FMT Services LLC located at 4516 Queenswood Drive, Grand Prairie, TX. We also conducted an inspection on September 11, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the FSVP implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>During our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your corn flour and quicklime imported from your foreign supplier \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and quicklime imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not have FSVPs for these products. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the initial FSVP inspection on September 11, 2018 and the follow-up inspection on March 22, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. As of the date of this letter, we have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for corn flour and quicklime imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and quicklime imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the corn flour and quicklime you import from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and quicklime you import from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP on Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Juan Daniel Garza III, Compliance Officer, US FDA, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact CO Garza via email at juan.garza@fda.hhs.gov. Please reference CMS# 614466 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Fabian Gonzalez\n\nRecipient Title\n\nOwner\n\nFMT Services, LLC\n\n4516 Queenswood Drive\n\nGrand Prairie, TX 75052-8332\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nJune 29, 2021\n\nWarning Letter\n\nCMS# 614466\n\nDear Mr. Gonzalez:\n\nOn March 22, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FMT Services LLC located at 4516 Queenswood Drive, Grand Prairie, TX. We also conducted an inspection on September 11, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the FSVP implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\n\nDuring our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your corn flour and quicklime imported from your foreign supplier (b)(4) and quicklime imported from your foreign supplier (b)(4). You did not have FSVPs for these products. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the initial FSVP inspection on September 11, 2018 and the follow-up inspection on March 22, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. As of the date of this letter, we have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for corn flour and quicklime imported from (b)(4); and quicklime imported from (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the corn flour and quicklime you import from (b)(4) and quicklime you import from (b)(4). We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP on Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Juan Daniel Garza III, Compliance Officer, US FDA, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact CO Garza via email at juan.garza@fda.hhs.gov. Please reference CMS# 614466 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision Director\n\nDivision of Southwest Imports","FMT Services, LLC","fmt-services-llc-614466-06292021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffmt-services-llc-614466-06292021","2026-10-26T08:08:42.489642+00:00","2021-09-21","614466","Mr. Fabian Gonzalez","2026-08-20T02:35:43.461+00:00","2021-06-29",7,{"510k":158,"classification":159,"enforcement":160,"event":161,"event_backfill":162,"pma":163,"warning_letter":164},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]